Invivyd (IVVD) Soars 32.77% on FDA Trial Clearance and Q3 Revenue Surge

On November 17, 2025, shares of Invivyd surged 32.77% in pre-market trading, driven by positive developments in its therapeutic pipeline and improved financial performance.

The stock’s rally follows the company’s Q3 2025 results, which showed a 40.2% year-over-year revenue increase to $13.13 million and a narrowed net loss of $10.47 million compared to $60.74 million in 2024. The FDA’s clearance to initiate pivotal trials for VYD2311, a next-generation antibody therapy, has positioned Invivyd as a key player in advancing infectious disease treatments beyond its existing product, PEMGARDA.

Investors are cautiously optimistic, as the trial progress validates the company’s strategy but does not fully address its reliance on a narrow product portfolio. The path to commercialization hinges on timely regulatory approvals and positive trial outcomes, which remain uncertain. Analysts note that while the current trajectory supports a long-term revenue projection of $349.7 million by 2028, achieving this will require consistent innovation and market acceptance.

Backtest assumptions suggest that a long position in Invivyd, initiated after the FDA clearance announcement, could benefit from momentum trading strategies. Historical volatility patterns indicate that key resistance levels may emerge at $7.50 and $10.00, aligning with projected fair value estimates. However, the strategy remains contingent on maintaining positive clinical data and avoiding regulatory setbacks.